With oil prices held higher by uncertainty around the Strait of Hormuz, attention is back on which companies can handle higher input and transport costs without fragile balance sheets. That is where a Financially Fit Penny Stocks screener becomes interesting. It filters for lower priced stocks that still show financial resilience. This article highlights three of the most compelling penny stocks from that universe for further research.

The three stocks covered below are just a small sample from this idea, as the full Financially Fit Penny Stocks screen surfaced 3,632 more companies with similarly compelling stories that are not included here. To identify and analyze the candidates that best fit your own criteria, head straight into the Financially Fit Penny Stocks screener.

Ardelyx (ARDX)

Ardelyx focuses on treatments for kidney and gastrointestinal conditions, with IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for managing high blood phosphate in adults on dialysis. All of its US$450.9 million in revenue comes from developing and commercializing these biopharmaceutical products, so the business is tightly tied to the success of this small group of therapies. The stock sits at around a US$997 million market cap, which puts Ardelyx firmly in the small cap biotech space.

Ardelyx stands out because it sits at the intersection of a large clinical need and meaningful earnings potential, supported by growing use of IBSRELA and XPHOZAH and analyst expectations for much stronger profitability over the next few years. At the same time, you are dealing with a highly concentrated product portfolio, ongoing reimbursement disputes around XPHOZAH and a relatively new management team, so execution and payer decisions matter a lot. The valuation signal from both analyst targets and discounted cash flow work suggests the market may be pricing those risks quite cautiously. This creates an opening for investors who understand the trade off and can track how guidance, margins and Medicare access evolve from here.

Ardelyx sits at a crossroads where growing use of IBSRELA and XPHOZAH could reshape its earnings profile. However, the real story is how analysts are sizing that shift. Get the full context in the analyst forecasts for Ardelyx

Build your own Ardelyx style shortlist

Ardelyx and the two other stocks in this article all came out of a single screener, but the real value is in shaping filters around what matters most to you. Use our flexible Screener to mix metrics like valuation, growth and balance sheet strength, or start with one of our curated Investing Ideas.

Alkane Resources (ASX:ALK)

Alkane Resources is an Australian gold producer that also has exposure to copper, nickel, zinc and silver, plus stakes in junior gold projects. This provides a mix of current production and exploration potential. The company sits at about A$2.1b in market cap, which puts it in the mid-tier space rather than among the smallest explorers.

Alkane Resources has become a three-mine producer with gold and antimony output, and the large Boda Kaiser gold copper project under development. The stock screens as potentially undervalued against estimated cash flow and earnings power. However, investors still need to consider factors such as higher-cost operations like Björkdal, board depth, and a future A$1.8b capex requirement at Boda Kaiser. For investors seeking a gold stock that combines current cash generation with a larger long-term project pipeline, Alkane may warrant a closer look.

Alkane Resources sits at the junction of current gold production and a huge Boda Kaiser build that could reshape the business, yet the market still prices in plenty of doubt. See how the analysis report for Alkane Resources hints at what that capex bill might really mean for investors.

Taboola.com (TBLA)

Taboola.com runs an AI-driven recommendation platform that plugs into publisher sites, devices and apps to serve both editorial content and ads across the open web. All of its roughly US$2 billion in revenue comes from advertising, with the United States the single largest country contributor within that total. The stock currently sits at about US$1.1b in market cap, keeping it in the small cap ad tech space.

Taboola.com sits at the point where AI powered ad targeting, first party data and open web partnerships could turn recent earnings momentum into something more durable. Revenue is tied to a single advertising segment, yet the company is pushing into performance ads through Realize and new monetization tools for generative AI, which could broaden its opportunity set if adoption holds. At the same time, funding relies entirely on external borrowing, one off items have had a big impact on reported profits and management still needs to prove that recent margin gains and index inclusions can withstand slower forecast growth. For investors who can weigh that trade off, the mix of a modest P/E, improving profitability and clear execution risks makes Taboola.com a penny stock that may warrant further research rather than a quick pass.

Taboola.com sits at the point where AI, first party data and open web partnerships could be pulling ahead of what its modest P/E implies. See how the analysis report for Taboola.com pulls together the upside story and the one factor that could still trip it up.

Seeking Fresh Alternatives Before They Fly

Fresh ideas move first. By the time a story hits every headline, the early window can be gone. Scan these curated stock lists while it matters and get in early.

• Spot companies with strong balance sheets before the crowd notices by running the list of solid balance sheet and fundamentals (48 results) and filter for businesses that already look prepared for tougher conditions.
• Explore potential momentum in quantum technology by scanning the 26 quantum computing stocks and focus your research on companies pushing real progress while they are still relatively under the radar.
• Identify cash generative AI opportunities by checking the 71 profitable AI stocks that aren't just burning cash and concentrate on businesses where revenues already support the story instead of relying only on hype.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.